Translational Pharmacology and Early Therapeutic Trials
Translational Pharmacology and Early Therapeutic Trials Program
The Translational Pharmacology and Early Therapeutic Trials Program (formerly Experimental Therapeutics Program) focuses on development of new cancer therapies. It conducts phase I and II trials in partnership with industry, NCI, and its own DF/HCC investigators. This Program provides toxicity information and pharmacokinetics for new agents, enabling implementation of phase II clinical trials. Another program goal is training clinical investigators in the science and regulatory aspects of drug development.
This Program is an essential conduit for preclinical and clinical development of agents identified in other DF/HCC programs, the NCI, and biotechnology/pharmaceutical companies. It has expanded by integrating its clinical trials activities with those of basic scientists in the discipline-based programs and clinical investigators in the clinical-based programs; this collaboration has broadened the scope of the program by providing expertise, advice, and collaboration in translational research to academic partners who wish to bring new agents into the clinical setting.
The scientific goals of the Program are:
- Conduct Phase I and I-II pharmacokinetic/pharmacodynamic trials of new cytotoxic agents, signal transduction inhibitors, differentiating agents, angiogenesis inhibitors, and anti-cancer vaccines.
- Facilitate pre-clinical & development of agents discovered within DF/HCC.
- Performance of translational studies to identify responsive subsets of tumors and confirm mechanism of action in the clinic.